UCB Japan

What UCB Japan does

UCB Japan Co. Ltd. (ユーシービージャパン株式会社) is the Japanese subsidiary of Belgian biopharmaceutical group UCB (Euronext Brussels: UCB), established in 1988 and headquartered in Shinjuku, Tokyo. The company manufactures and commercializes prescription pharmaceuticals in three therapeutic franchises: neurology (epilepsy drugs Vimpat, Briviact, Fintepla), immunology/inflammation (Cimzia for rheumatoid arthritis, Bimzelx for psoriasis and HS), and rare diseases (Rystiggo and Zilbrysq for generalized myasthenia gravis). It operates a manufacturing facility in Saitama, integrated from the Izumizaki site in 2001, and holds pharmaceutical manufacturing and import sales licenses.

The business model is sales-led: UCB Japan generates revenue from prescription drug sales through pharmaceutical wholesalers to hospitals, clinics, and pharmacies, complemented by a growing direct sales organization. The company has progressively transitioned major assets from co-promotion with partners (Daiichi Sankyo for Vimpat, Astellas for select products) to self-commercialization, with E Keppra (2020), Simponi (2025), Cimzia (2025), and Vimpat (2026) now sold direct. It targets two primary customer segments: patients with severe neurological, immunological, and bone diseases, and the healthcare professionals who treat them. Pricing follows the Japanese national health insurance reimbursement framework and is not publicly disclosed.

UCB Japan supports its franchises through patient education portals (UCBCares, My colorinG for gMG, WoCBA for RA) and a healthcare professional portal (hcp.ucbcares.jp), and runs disease-awareness campaigns. Recent strategic activity centers on rare disease expansion (Rystiggo 2023, Zilbrysq 2024), label and formulation extensions (Briviact pediatric/dry syrup filing 2026), portfolio rationalization (Fintepla transferred to Nippon Shinyaku in 2026), and a co-development partnership with Biogen on dapirolizumab pegol for systemic lupus erythematosus. UCB Group employs approximately 9,000 people globally and reported €6.1 billion in FY2024 revenue; UCB Japan is privately held as a wholly-owned subsidiary.

Name

UCB Japan

Legal name

UCB Japan Co. Ltd. (ユーシービージャパン株式会社)

Website

https://ucbjapan.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

51–100 employees

Short description

UCB Japan is the Japanese subsidiary of Belgian biopharma UCB Group, commercializing prescription drugs in neurology (epilepsy), immunology/inflammation (rheumatoid arthritis, psoriasis, HS), and rare diseases (myasthenia gravis), serving physicians, pharmacists, and patients through wholesalers and a growing direct sales organization.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Dermatology Specialty Pharmaceuticals (HLAIACAL), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Prescription pharmaceuticals
• Neurology therapeutics
• Immunology treatments
• Rare disease therapeutics
• Biopharmaceutical products

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: UCB Japan generates revenue through the sale of prescription pharmaceutical products in Japan, focusing on neurology, immunology/inflammation, and bone disease therapeutic areas. The company markets drugs for epilepsy, rheumatoid arthritis, psoriasis, osteoporosis, and rare diseases.
2. Product Commercialization: Revenue from commercializing innovative pharmaceutical products including anti-epilepsy drugs, rheumatoid arthritis treatments, psoriasis treatments, and rare disease therapeutics. The company has transitioned to self-distribution models for certain products (e.g., Vimpat sales transferred from Daiichi Sankyo to UCB Japan in 2026).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

UCB Japan develops, manufactures (at its Saitama factory), and commercializes prescription pharmaceutical products in Japan focused on neurology (epilepsy treatments Vimpat®, Briviact®, Fintepla®; myasthenia gravis treatments Rystiggo®, Zilbrysq®), immunology/inflammation (Cimzia® for rheumatoid arthritis; Bimzelx® for psoriasis and hidradenitis suppurativa), and bone disease. The company sells through pharmaceutical wholesalers and increasingly via its own direct sales organization to medical institutions, supported by the UCBCares patient and HCP digital portals.

Product overview

UCB Japan is a biopharmaceutical company specializing in neurology, immunology/inflammation, and rare diseases. The product portfolio includes antiepileptic drugs (Vimpat®, Briviact®, Fintepla®), rheumatoid arthritis treatment (Cimzia®), psoriasis and immunology treatments (Bimzelx®), and rare disease treatments for myasthenia gravis (Rystiggo®, Zilbrysq®). The company also operates patient support platforms through UCBCares for disease education and resources. Since 2023, UCB Japan has expanded into rare disease treatments and transitioned to direct sales organizations for several products.

Differentiator

Problem solved

Functional benefit

Products and services

• Vimpat® (ビムパット®) Anti-epileptic medication for seizure treatment, available in tablets, dry syrup, and IV infusion forms. Prescribed for epilepsy patients.
• Briviact® (ブリィビアクト®) Anti-epileptic medication approved for epilepsy treatment, available in tablet and IV forms with a dry syrup formulation under application.
• Cimzia® (シムジア®) Biologic medication for rheumatoid arthritis treatment in adult patients.
• Bimzelx® (ビンゼレックス®) Biologic treatment for immunology and inflammation indications including plaque psoriasis and hidradenitis suppurativa.
• Rystiggo® (リスティーゴ®) Subcutaneous injection treatment for adult patients with generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disease.
• Zilbrysq® (ジルブリスク®) Subcutaneous injection treatment for generalized myasthenia gravis, available in 16.6mg, 23.0mg, and 32.4mg auto-injector formats.
• UCBCares Patient Portal Patient support and information portal (ucbcares.jp) providing disease education, treatment information, and community resources for patients in neurology, immunology, and rare disease areas including epilepsy, hidradenitis suppurativa, myasthenia gravis, psoriasis, osteoporosis, and rheumatoid arthritis.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• BiogencoreStrategic or Co-development Partner · 23 June 2026UCB and Biogen collaboration on dapirolizumab pegol (DZP) Phase III clinical trial for systemic lupus erythematosus (SLE). Positive Phase III results published in The Lancet. This represents a co-development partnership in immunology.
• Belgium-Japan 160th Anniversary SponsorshipminorOthers · 21 May 2026UCB served as Platinum sponsor for the Belgium-Japan 160th Anniversary Friendship commemorative business events. Demonstrates corporate citizenship and ties to Belgian parent company heritage.
• Daiichi Sankyo (第一三共株式会社)minorChannel Partner/ Reseller/ Distributor · 2 March 2026Previously co-promoted Vimpat (ビムパット) with Daiichi Sankyo in Japan. Co-commercialization agreement ended in March 2026, with full sales rights transferred to UCB Japan. Historical distribution partnership that transitioned to self-commercialization.
• Nippon Shinyaku (日本新薬株式会社)minorChannel Partner/ Reseller/ Distributor · 24 February 2026Manufacturing and marketing authorization for Fintepla (フィンテプラ) 内用液2.2mg/mL for epilepsy seizure treatment was succeeded to Nippon Shinyaku. UCB transferred the manufacturing and marketing rights in Japan.
• Astellas Pharma (アステラス製薬株式会社)minorStrategic or Co-development PartnerAstellas is listed as a co-promotion partner for certain products and is included in joint data utilization arrangements. Also handles inquiries for co-promoted products.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Takeda Pharmaceutical Company Limited: Japan's largest pharma with global footprint; overlaps in neurology, rare diseases, and immunology. Comparable as a broad incumbent with extensive Japan field force.
• Astellas Pharma Inc. Large Japanese pharma operating broadly in immunology, rare diseases, and specialty care; existing co-promotion partner of UCB Japan. Compares as a broader incumbent with overlapping therapeutic areas.
• Daiichi Sankyo Co., Ltd. Major Japanese pharma and former co-promotion partner for Vimpat; representative of the larger established commercial players against which UCB Japan's direct sales build-out competes.

Direct peers

• Nippon Shinyaku Co., Ltd. Mid-cap Japanese specialty pharma with strong rare disease and neurology focus; recently acquired Fintepla rights from UCB Japan. Directly comparable therapeutic mix and scale profile.
• Otsuka Pharmaceutical Co., Ltd. Japanese pharma with strong CNS/neurology franchise (including epilepsy and psychiatry). Comparable therapeutic focus and mid-to-large scale Japan operations.
• Kyowa Kirin Co., Ltd. Japan-based specialty pharma with focus on immunology, rare diseases, and bone; comparable portfolio diversification strategy and Japan-anchored commercialization.
• Sumitomo Pharma Co., Ltd. Mid-cap Japanese specialty pharma active in CNS, oncology, and rare diseases; comparable therapeutic breadth and mid-sized commercial organization in Japan.
• Eisai Co., Ltd. Japanese specialty pharma with deep neurology franchise (epilepsy, dementia) and direct overlap with UCB Japan's antiepileptic portfolio. Comparable in size, therapeutic focus, and Japan-centric commercialization model.

Others

• Biogen Inc. US-based biotech with neurology and immunology focus and active co-development partner on DZP for SLE. Comparable therapeutic alignment; engaged as a strategic ecosystem partner rather than direct competitor.
• UCB Group (Belgium): Parent company and ultimate portfolio owner; provides the pipeline, capital, and strategic direction that UCB Japan executes. Included as the controlling ecosystem participant rather than a competitive peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/ucb_news
• YouTubeyoutube.com/UCB
• Facebookfacebook.com/UCBBiopharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCB Japan